Xenetic Biosciences
XBIO
19 hedge funds and large institutions have $3.43M invested in Xenetic Biosciences in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
312% more capital invested
Capital invested by funds: $832K → $3.43M (+$2.6M)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
36% more funds holding
Funds holding: 14 → 19 (+5)
1.26% more ownership
Funds ownership: 0.47% → 1.72% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.58M |
| 2 |
Renaissance Technologies
New York
|
+$757K |
| 3 |
Two Sigma Investments
New York
|
+$444K |
| 4 |
Two Sigma Advisers
New York
|
+$423K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$51K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$20K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$10K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.98K |
XBIO Hedge Fund Activity: Q3 2021 in Review
19 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2021, worth a combined $3.43M — up 312% from $832K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XBIO positions and 4 closed out — a net gain of 5 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.58M. The largest seller was Citadel Advisors, exiting entirely with an estimated $104K sold.
- 19 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2021, up from 14 in Q2 2021.
- Funds reported $3.43M of Xenetic Biosciences stock for Q3 2021, up 312% quarter-over-quarter.
- 9 funds opened new Xenetic Biosciences positions in Q3 2021 and 4 closed out, a net change of +5 holders.
- The largest Xenetic Biosciences buyer in Q3 2021 was Armistice Capital, an estimated $1.58M added.
- The largest Xenetic Biosciences seller in Q3 2021 was Citadel Advisors, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2021.